These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605 [TBL] [Abstract][Full Text] [Related]
25. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation. Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C Front Immunol; 2020; 11():577. PubMed ID: 32391001 [TBL] [Abstract][Full Text] [Related]
26. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression. Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189 [TBL] [Abstract][Full Text] [Related]
28. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model. Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS Front Immunol; 2021; 12():737076. PubMed ID: 34659228 [TBL] [Abstract][Full Text] [Related]
29. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714 [TBL] [Abstract][Full Text] [Related]
30. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma. Martin de la Fuente L; Westbom-Fremer S; Arildsen NS; Hartman L; Malander S; Kannisto P; Måsbäck A; Hedenfalk I Virchows Arch; 2020 Jul; 477(1):83-91. PubMed ID: 31980961 [TBL] [Abstract][Full Text] [Related]
32. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Wang W; Zou W; Liu JR Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508 [No Abstract] [Full Text] [Related]
33. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267 [TBL] [Abstract][Full Text] [Related]
34. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS Front Immunol; 2020; 11():7. PubMed ID: 32117218 [TBL] [Abstract][Full Text] [Related]
36. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043 [TBL] [Abstract][Full Text] [Related]
37. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
38. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine. Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878 [TBL] [Abstract][Full Text] [Related]
39. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
40. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy. Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]